Loading patent…
AssigneeNovartis AG
InventorsKlaus Seuwen, Eric Billy, Thomas Suply, Lorenza Wyder, Janet Dawson King, Marie-Gabrielle Ludwig, Matthias Mueller, Puneeta Nath, Carol Elizabeth Jones
Estimating the term…
The present invention relates to the use of a GPR4 inhibitor for the manufacture of a medicament for the inhibition of angiogenesis, for instance for the inhibition of tumour growth in the treatment of cancer. In a preferred embodiment, said inhibitor is a siRNA, preferably double-stranded. In addition, the present invention further encompasses non-human animals wherein the GPR4 has been inactivated, for instance a knock-out mouse lacking GPR4, and the use of said animals as an experimental model for angiogenesis and for screening for compounds modulating angiogenesis.
Use of a GPR4 inhibitor for the manufacture of a medicament for the inhibition of angiogenesis.
A siRNA molecule comprising the sequence of SEQ ID NO:1-20.
A non human animal wherein the gene coding for GPR4 has been deleted.
A method of or for identifying an inhibitor of GPR4 (e.g. human GPR4) for use in a method of manufacturing a medicament for the treatment of a human patient afflicted with a disease selected from;
Dependencies are inferred from the claim text.